PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gadoteric Acid→

Gadoteric Acid PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
72573-82-1
Molecular formula
C16H25GdN4O8
Molecular weight
558.65 g/mol
Drug class
Macrocyclic gadolinium-based paramagnetic MRI contrast agent
Mechanism of action
A macrocyclic gadolinium chelate that shortens the T1 and T2 relaxation times of nearby water protons in a magnetic field, increasing signal intensity in MRI.
Indications / reported uses
  • Contrast enhancement in MRI of the brain, spine and other body regions where disruption of the blood-brain barrier or abnormal vascularity is being evaluated, according to the product label.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/158536 · https://www.gov.uk/drug-safety-update/gadolinium-containing-contrast-agents-removal-of-omniscan-and-iv-magnevist-restrictions-to-the-use-of-other-linear-agents

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Gadoteric Acid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gadoteric Acid Permitted Daily Exposure (PDE) report (the Gadoteric Acid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gadoteric Acid Occupational Exposure Limit (OEL) report (the Gadoteric Acid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.